和元生物：公司已协助客户获得多个国内外IND批件，其产品类型包括CAR-T、Treg、干细胞等

Core Insights - AbbVie is acquiring Capstan Therapeutics for $2.1 billion to enhance its product line in immunological diseases through mRNA-based CAR-T therapy [2] - Yuan Sheng Bio has made significant advancements in CAR-T technology, including improvements in lentiviral vector technology and the establishment of an mRNA CAR-T electroporation platform [2] Group 1: AbbVie's Acquisition - AbbVie is expanding its capabilities in CAR-T therapy by acquiring Capstan Therapeutics for $2.1 billion [2] - The acquisition aims to strengthen AbbVie's product offerings in the field of immunological diseases [2] Group 2: Yuan Sheng Bio's Technological Advancements - Yuan Sheng Bio has achieved a 90% positive rate in NK cell transduction through optimized lentiviral vector technology [2] - The company has overcome challenges in the production process, enhancing the titer of lentiviral vectors [2] - Yuan Sheng Bio has successfully built an mRNA CAR-T electroporation platform and made breakthroughs in enhanced CAR-T project processes [2] - The company is collaborating strategically to develop advanced mRNA-LNP non-viral vector technologies for in-vivo CAR-T therapies [2] - Yuan Sheng Bio has established a T-Flash short-term autologous CAR-T process and applied it to client IND projects [2] - As of Q1 2025, the company has assisted clients in obtaining multiple IND approvals for various product types, including CAR-T, Treg, and stem cells [2]